Vitroscope
Vitroscope, based in Trondheim, Norway, keeps living human tissue, vascularized organoids and tissue slices alive under controlled perfusion, generating longitudinal, comparable biological data for drug discovery and translational research at pharma companies, CROs and academic labs.
Position in SVTRnew
Snapshot 2026-11-05- Startup SignalsRankedof 2,340
- Life SciencesRankedof 248
- Drug DiscoveryRankedof 69
- Data AcquisitionRankedof 33
About
Vitroscope, based in Trondheim, Norway, keeps living human tissue, vascularized organoids and tissue slices alive under controlled perfusion, generating longitudinal, comparable biological data for drug discovery and translational research at pharma companies, CROs and academic labs. Products include the benchtop vitro.alive system and the high-throughput vitro.scale platform in development.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Company· 8
Investor· 7
Founders / team· 3
Funding history
- 2026-11-03Seed$5M
Investors · Cerberus Ventures, YZR Capital, Arcas Ventures, Golden Egg Check, Devico Invest, Fàtima Godall, Oskari PétasSource · vitroscope.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Vitroscope
Vitroscope, based in Trondheim, Norway, keeps living human tissue, vascularized organoids and tissue slices alive under controlled perfusion…
Seed · $9M · 2026-11
$9M
United States
BusinessLatest roundTotal raisedDate- Onepot
Small-molecule synthesis for drug discovery for biopharma companies (AI + automated synthesis)
Seed · $13M · 2025-11
$13M - Pepper Bio
Analyzes multi-layer biological data (including DNA, RNA, proteomic and phosphoproteomic data) to discover new drugs
Seed · $7M · 2023-12
$7M - Integrated Biosciences
Drugs for age-related diseases developed with synthetic biology and AI
Seed · $17M · 2024-10
$17M
China
BusinessLatest roundTotal raisedDate- Coherence Biotech Co. Ltd.
Lab automation: the Keystone™ benchtop all-in-one system combines culturing…
— - 元示科技
AI Virtual Cell (AIVC): a raw biological data engine and general-purpose cell foundation model forming a life sciences base…
Angel · 2026-10
— - Anew Labs
AI-driven drug discovery and new drug development platform
Undisclosed · $290M · 2026-09 · Valuation $1.5B
$290MValuation $1.5B
Europe
BusinessLatest roundTotal raisedDate- Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M - Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M - Cyclana Bio
Tissue-level drug discovery model for treating endometriosis
Pre-Seed · $7M · 2025-10
$7M
Other / unspecified
BusinessLatest roundTotal raisedDate- ChemT Biotechnology
CelMo AI virtual cell platform helping biopharma/CDMO companies improve cell culture and antibody production efficiency
Seed · $5M · 2026-06
$5M - Elixion Biotech
Cancer drug target discovery platform driven by quantum physics, causal biology, multi-omics and AI
— - Astellas Pharma
Research, manufacturing and sale of prescription drugs in oncology, ophthalmology, urology, immunology and women's health.
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
38 Life Sciences deals in the last 24 months · 17 at a nearby stage · 2 in Northern Europe
Request intro →Lightspeed
16 Life Sciences deals in the last 24 months · 5 at a nearby stage · 2 in Northern Europe
Request intro →LifeX Ventures
8 Life Sciences deals in the last 24 months · 5 at a nearby stage · 1 in Northern Europe
Request intro →Amino Collective
6 Life Sciences deals in the last 24 months · 5 at a nearby stage · 2 in Northern Europe
Request intro →Kinnevik
6 Life Sciences deals in the last 24 months · 1 at a nearby stage · 2 in Northern Europe
Request intro →Calm/Storm Ventures
4 Life Sciences deals in the last 24 months · 4 at a nearby stage · 1 in Northern Europe
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.